The Japan Times - Once-taboo ketamine booms for US at-home mental care

EUR -
AED 4.306924
AFN 77.800612
ALL 96.290273
AMD 447.455848
ANG 2.099694
AOA 1075.411417
ARS 1700.779101
AUD 1.772061
AWG 2.110949
AZN 1.988177
BAM 1.952553
BBD 2.365276
BDT 143.51133
BGN 1.955558
BHD 0.44213
BIF 3482.009164
BMD 1.17275
BND 1.514082
BOB 8.114505
BRL 6.462082
BSD 1.174352
BTN 106.720516
BWP 15.510205
BYN 3.441491
BYR 22985.892779
BZD 2.361882
CAD 1.615644
CDF 2638.686581
CHF 0.934332
CLF 0.027329
CLP 1072.104138
CNY 8.258444
CNH 8.255383
COP 4504.50788
CRC 586.025397
CUC 1.17275
CUP 31.077865
CVE 110.081926
CZK 24.301712
DJF 209.123105
DKK 7.471107
DOP 75.454514
DZD 151.827002
EGP 55.592317
ERN 17.591244
ETB 182.304714
FJD 2.673278
FKP 0.876507
GBP 0.876073
GEL 3.160551
GGP 0.876507
GHS 13.505539
GIP 0.876507
GMD 86.199295
GNF 10212.016669
GTQ 8.993044
GYD 245.691397
HKD 9.122608
HNL 30.940544
HRK 7.53222
HTG 153.794229
HUF 385.778924
IDR 19582.573348
ILS 3.789201
IMP 0.876507
INR 105.893078
IQD 1538.448008
IRR 49399.146865
ISK 147.995144
JEP 0.876507
JMD 188.486533
JOD 0.831511
JPY 181.991394
KES 151.226201
KGS 102.55723
KHR 4702.179931
KMF 492.554939
KPW 1055.474962
KRW 1735.464253
KWD 0.359705
KYD 0.978677
KZT 605.335863
LAK 25442.795245
LBP 105164.352354
LKR 363.536961
LRD 207.864306
LSL 19.721186
LTL 3.462825
LVL 0.709385
LYD 6.362446
MAD 10.746727
MDL 19.776195
MGA 5305.177102
MKD 61.535274
MMK 2462.499847
MNT 4159.55763
MOP 9.41009
MRU 46.575541
MUR 54.005329
MVR 18.072469
MWK 2036.313462
MXN 21.065457
MYR 4.791838
MZN 74.950137
NAD 19.721186
NGN 1704.791285
NIO 43.218125
NOK 11.959003
NPR 170.753025
NZD 2.030505
OMR 0.450919
PAB 1.174347
PEN 3.955921
PGK 4.992697
PHP 68.680904
PKR 329.11566
PLN 4.216211
PYG 7887.915449
QAR 4.281779
RON 5.091849
RSD 117.371155
RUB 92.705885
RWF 1709.856384
SAR 4.398673
SBD 9.573626
SCR 16.573783
SDG 705.411284
SEK 10.921847
SGD 1.515386
SHP 0.879866
SLE 27.90959
SLL 24591.977696
SOS 671.183772
SRD 45.359637
STD 24273.549601
STN 24.459322
SVC 10.275954
SYP 12968.817782
SZL 19.704314
THB 36.88356
TJS 10.792352
TMT 4.116351
TND 3.429397
TOP 2.8237
TRY 50.099067
TTD 7.966785
TWD 37.020192
TZS 2899.859147
UAH 49.525635
UGX 4181.046614
USD 1.17275
UYU 45.943592
UZS 14239.318971
VES 320.446921
VND 30897.848168
VUV 142.444302
WST 3.259438
XAF 654.867907
XAG 0.017685
XAU 0.00027
XCD 3.169414
XCG 2.116489
XDR 0.814446
XOF 654.870694
XPF 119.331742
YER 279.524973
ZAR 19.649713
ZMK 10556.150373
ZMW 26.981243
ZWL 377.624903
  • SCS

    0.0200

    16.14

    +0.12%

  • CMSD

    0.0150

    23.38

    +0.06%

  • RBGPF

    0.4100

    82.01

    +0.5%

  • NGG

    -0.2600

    75.77

    -0.34%

  • CMSC

    0.0400

    23.34

    +0.17%

  • GSK

    -0.4600

    48.78

    -0.94%

  • RELX

    -0.2600

    40.82

    -0.64%

  • BCC

    0.5100

    75.84

    +0.67%

  • BCE

    -0.2800

    23.33

    -1.2%

  • RIO

    0.1700

    75.99

    +0.22%

  • BTI

    -0.4500

    57.29

    -0.79%

  • JRI

    -0.0500

    13.51

    -0.37%

  • VOD

    0.0000

    12.7

    0%

  • RYCEF

    -0.3100

    14.64

    -2.12%

  • AZN

    -0.2100

    91.35

    -0.23%

  • BP

    -1.4900

    33.76

    -4.41%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

M.Yamazaki--JT